Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells

Joseph Cataquiz Rimando, Ezhilarasi Chendamarai, Michael P Rettig, Reyka G Jayasinghe, Matthew Christopher, Julie K Ritchey, Stephanie Christ, Miriam Kim, Ezio Bonvini, John F. DiPersio

Blood blood.2022017795.

DOI: https://doi.org/10.1182/blood.2022017795

Published: 2022

Includes: Supplemental data

Journal Articles

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 1570–1571.

DOI: https://doi.org/10.1182/blood-2022-157726

Published: 2022

Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio

Blood (2022) 140 (Supplement 1): 8795–8796.

DOI: https://doi.org/10.1182/blood-2022-156943

Published: 2022

Journal Articles

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Parmeshwar N. Amatya, Reyka G. Jayasinghe, Alun J. Carter, Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Julie K. Ritchey

Blood (2022) 140 (Supplement 1): 12686–12687.

DOI: https://doi.org/10.1182/blood-2022-167715

Published: 2022

Journal Articles

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 4477–4478.

DOI: https://doi.org/10.1182/blood-2022-159734

Published: 2022

Journal Articles

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Ezhilarasi Chendamarai, Julie K. Ritchey, Leah Gehrs, Michael P. Rettig, Sai Mukund Ramakrishnan, Christopher A Miller, George Cox, Lana Anderson, Timothy J Ley, John F. DiPersio

Blood (2022) 140 (Supplement 1): 7345–7346.

DOI: https://doi.org/10.1182/blood-2022-167415

Published: 2022

Journal Articles

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Miriam Y Kim, Matthew L Cooper, Julie K Ritchey, Julia Hollaway, John F. DiPersio

Blood (2021) 138 (Supplement 1): 734.

DOI: https://doi.org/10.1182/blood-2021-150935

Published: 2021

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

DOI: https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Parmeshwar N Amatya, PhD, Alun J Carter, PhD BSc, Julie K Ritchey, Jessica Niswonger, Matthew L Cooper, PhD, Jonathan A Pachter, PhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-139904

Published: 2020

Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

DOI: https://doi.org/10.1182/blood-2020-133891

Published: 2020

Journal Articles

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Daniel Cancilla, BS, Haresh Thakellapalli, Marvin J Meyers, PhD, Michael P. Rettig, PhD, Ezhilarasi Chendamarai, PhD, Stephanie Christ, MS, Darja Karpova, PhD, Peter G Ruminski, BS, Julie K. Ritchey, Dwight M. Morrow, PhD, Michael Prinsen, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 1916.

DOI: https://doi.org/10.1182/blood-2019-124373

Published: 2019

Journal Articles

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Stephen P. Persaud, MD PhD, Matthew L. Cooper, PhD, Julie K. Ritchey, Michael P. Rettig, PhD, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 3200.

DOI: https://doi.org/10.1182/blood-2019-123519

Published: 2019

Journal Articles

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Kidist Ashami, BA, Sena Kim, PhD, Ravi Vij, MBBS, Julie K. Ritchey, Srikanth Santhanam, PhD, Sora Lim, MS, Sarah Peterson, Matthew Ciorba, MD, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2019) 134 (Supplement_1): 4420.

DOI: https://doi.org/10.1182/blood-2019-126167

Published: 2019

Journal Articles

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Armin Ghobadi, Michael P. Rettig, Matthew S. Holt, Julie K. Ritchey, Krista Kennerly, Ezhilarasi Chendamarai, Linda Eissenberg, John F. DiPersio

Blood (2018) 131 (23): 2594–2596.

DOI: https://doi.org/10.1182/blood-2017-10-811620

Published: 2018

Journal Articles

Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells

Darja Karpova, Julie K. Ritchey, Matthew S. Holt, Grazia Abou-Ezzi, Darlene Monlish, Lena Batoon, Susan Millard, Gabriele Spohn, Eliza Wiercinska, Ezhil Chendamarai, Wei Yang, Stephanie Christ, Leah Gehrs, Laura G. Schuettpelz, Klaus Dembowsky, Allison R. Pettit, Michael P. Rettig, Halvard Bonig, John F. DiPersio

Blood (2017) 129 (21): 2939–2949.

DOI: https://doi.org/10.1182/blood-2016-10-746909

Published: 2017

Includes: Supplemental data

Journal Articles

Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform

Muneera Al-Hussaini, Michael P. Rettig, Julie K. Ritchey, Darja Karpova, Geoffrey L. Uy, Linda G. Eissenberg, Feng Gao, William C. Eades, Ezio Bonvini, Gurunadh R. Chichili, Paul A. Moore, Syd Johnson, Lynne Collins, John F. DiPersio

Blood (2016) 127 (1): 122–131.

DOI: https://doi.org/10.1182/blood-2014-05-575704

Published: 2016

Includes: Supplemental data

Journal Articles

Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis

Armin Ghobadi, Michael P. Rettig, Matthew L. Cooper, Matthew S. Holt, Julie K. Ritchey, Linda Eissenberg, John F. DiPersio

Blood (2014) 124 (17): 2752–2754.

DOI: https://doi.org/10.1182/blood-2014-08-595967

Published: 2014

Journal Articles

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells

Pablo Ramirez, Michael P. Rettig, Geoffrey L. Uy, Elena Deych, Matthew S. Holt, Julie K. Ritchey, John F. DiPersio

Blood (2009) 114 (7): 1340–1343.

DOI: https://doi.org/10.1182/blood-2008-10-184721

Published: 2009

Includes: Supplemental data

Journal Articles

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Bruno Nervi, Pablo Ramirez, Michael P. Rettig, Geoffrey L. Uy, Matthew S. Holt, Julie K. Ritchey, Julie L. Prior, David Piwnica-Worms, Gary Bridger, Timothy J. Ley, John F. DiPersio

Blood (2009) 113 (24): 6206–6214.

DOI: https://doi.org/10.1182/blood-2008-06-162123

Published: 2009

Includes: Supplemental data

Journal Articles

Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.

Michael P. Rettig, PhD, Pablo Ramirez, M.D., William D. Shannon, Ph.D., Geoffrey L. Uy, M.D., Sandra Lopez, Julie K. Ritchey, John F. DiPersio, M.D./Ph.D.

Blood (2007) 110 (11): 1203.

DOI: https://doi.org/10.1182/blood.V110.11.1203.1203

Published: 2007

NARROW

Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells

Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform

Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only